Type 2 Autoimmune Hepatitis: Genetic Susceptibility

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Oct 17

PMID 36248826

Authors

Pascal Lapierre

Fernando Alvarez

Affiliations

Soon will be listed here.

Abstract

Two types of autoimmune hepatitis (AIH) are recognized; AIH-1 is characterized by the presence of anti-nuclear and/or anti-smooth muscle autoantibodies, while AIH-2 is associated with the presence of anti-Liver kidney microsome and/or anti-Liver Cytosol antibodies. The autoantigens targeted by AIH-2 autoantibodies are the cytochrome P450 2D6 and Formiminotransferase-cyclodeaminase for anti-LKM1 and anti-LC1 respectively. Both autoantigens are expressed in hepatocytes at higher levels than in any other cell type. Therefore, compared to AIH-1, the autoantigens targeted in AIH-2 are predominantly tissue-specific. Distinct clinical features are specific to AIH-2 compared to AIH-1, including diagnosis in younger patients (mean age 6.6 years), onset as fulminant hepatitis in very young patients (3 years of age or less), higher frequency in children than in adults and is frequently associated with extrahepatic T cell-mediated autoimmune diseases. AIH-2 is also often diagnosed in patients with primary immunodeficiency. AIH-2 is associated with specific HLA class II susceptibility alleles; DQB1*0201 is considered the main determinant of susceptibility while DRB1*07/DRB1*03 is associated with the type of autoantibody present. HLA DQB1*0201 is in strong linkage disequilibrium with both HLA DRB1*03 and DRB1*07. Interestingly, as in humans, MHC and non-MHC genes strongly influence the development of the disease in an animal model of AIH-2. Altogether, these findings suggest that AIH-2 incidence is likely dependent on specific genetic susceptibility factors combined with distinct environmental triggers.

Citing Articles

A Rare Overlap: Sjögren's Syndrome With Autoimmune Hepatitis.

Prasaanth S, Sivasubramanian D Cureus. 2024; 16(11):e74334.

PMID: 39720387 PMC: 11667356. DOI: 10.7759/cureus.74334.

Autoimmune hepatitis: Towards a personalized treatment.

Costaguta A, Costaguta G, Alvarez F World J Hepatol. 2024; 16(11):1225-1242.

PMID: 39606175 PMC: 11586748. DOI: 10.4254/wjh.v16.i11.1225.

B cell depletion for autoimmune liver diseases: A retrospective review of indications and outcomes.

Costaguta G, Alvarez F JPGN Rep. 2024; 5(3):326-333.

PMID: 39149184 PMC: 11322033. DOI: 10.1002/jpr3.12098.

Prevalence of autoimmune thyroiditis among children with autoimmune hepatitis.

Mogahed E, Soliman H, Morgan D, Elaal H, Khattab R, Eid R Ital J Pediatr. 2024; 50(1):72.

PMID: 38632644 PMC: 11025222. DOI: 10.1186/s13052-024-01639-4.

HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment.

Gandarillas S, Newland E, Toppmeyer D, Stephenson R, Denzin L, Dasgeb B Front Med (Lausanne). 2024; 10:1288844.

PMID: 38259857 PMC: 10800809. DOI: 10.3389/fmed.2023.1288844.

References

Goldberg A, Bittencourt P, Oliveira L, Ramasawmy R, Marin M, Palacios S . Autoimmune hepatitis in Brazil: an overview. Scand J Immunol. 2007; 66(2-3):208-16. DOI: 10.1111/j.1365-3083.2007.01967.x. View

Gregorio G, Portmann B, Reid F, Donaldson P, Doherty D, McCartney M . Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997; 25(3):541-7. DOI: 10.1002/hep.510250308. View

Bonito A, Aloman C, Fiel M, Danzl N, Cha S, Weinstein E . Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest. 2013; 123(8):3510-24. PMC: 3726151. DOI: 10.1172/JCI65414. View

Marceau G, Lapierre P, Beland K, Soudeyns H, Alvarez F . LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry?. Hepatology. 2005; 42(3):675-82. DOI: 10.1002/hep.20816. View

de Boer Y, Gerven N, Zwiers A, Verwer B, van Hoek B, van Erpecum K . Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014; 147(2):443-52.e5. DOI: 10.1053/j.gastro.2014.04.022. View

Vorechovsky I, Webster A, Plebani A, Hammarstrom L . Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition. Am J Hum Genet. 1999; 64(4):1096-109. PMC: 1377834. DOI: 10.1086/302326. View

Donaldson P . Immunogenetics in liver disease. Baillieres Clin Gastroenterol. 1996; 10(3):533-49. DOI: 10.1016/s0950-3528(96)90056-1. View

Rook G, Steele J, Ainsworth M, Champion B . Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology. 1986; 59(3):333-8. PMC: 1453207. View

Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F . Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol. 2004; 40(6):904-9. DOI: 10.1016/j.jhep.2004.02.023. View

10.

Scully L, Toze C, Sengar D, Goldstein R . Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology. 1993; 104(5):1478-84. DOI: 10.1016/0016-5085(93)90359-k. View

11.

Czaja A, Carpenter H, Moore S . Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Liver Int. 2006; 26(5):552-8. DOI: 10.1111/j.1478-3231.2006.01249.x. View

12.

Czaja A, Souto E, Bittencourt P, Cancado E, Porta G, Goldberg A . Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002; 37(3):302-8. DOI: 10.1016/s0168-8278(02)00182-4. View

13.

Yuksel M, Wang Y, Tai N, Peng J, Guo J, Beland K . A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology. 2015; 62(5):1536-50. PMC: 4763614. DOI: 10.1002/hep.27998. View

14.

Czaja A, Cookson S, Constantini P, Clare M, Underhill J, Donaldson P . Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology. 1999; 117(3):645-52. DOI: 10.1016/s0016-5085(99)70458-0. View

15.

Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F . A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology. 2004; 39(4):1066-74. DOI: 10.1002/hep.20109. View

16.

Hiraide A, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K . Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol. 2005; 100(6):1322-9. DOI: 10.1111/j.1572-0241.2005.41053.x. View

17.

Lapierre P, Beland K, Martin C, Alvarez Jr F, Alvarez F . Forkhead box p3+ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology. 2010; 51(5):1789-98. DOI: 10.1002/hep.23536. View

18.

Ma Y, Su H, Yuksel M, Longhi M, McPhail M, Wang P . Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry. Hepatology. 2021; 74(4):2032-2046. PMC: 8463472. DOI: 10.1002/hep.31893. View

19.

Schubert D, Bode C, Kenefeck R, Hou T, Wing J, Kennedy A . Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014; 20(12):1410-1416. PMC: 4668597. DOI: 10.1038/nm.3746. View

20.

Kirk A, Jain S, Pocock S, Thomas H, Sherlock S . Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 1980; 21(1):78-83. PMC: 1419564. DOI: 10.1136/gut.21.1.78. View